News 
Market Data 
Discover
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
convertible notes I guess.....
CDIX Monster Move coming!
Great what they say???
Let's get some Ho Ho Ho $$$! $CDIX
Same here. I've seen stocks with great news like this just get crushed for a few days until the MMs get all the supply they want from traders who capitulate because they want immediate rewards, and then the stock rises like an Elon Musk rocket, usually with me watching from the sidelines. Even though there's some question about this capital structure, the income news alone justifies a much higher stock price. And there's certainly a lot more upside potential than downside risk. So I'm holding and will add once I sense it's built a solid base and is ready to move higher..
rockie101, with those thoughts...
I think the selling in CDIX is an overreaction from traders and not investors. I think that it should recover and transform into some big.
Think about why the 1-75,000 reverse slit ratio makes no sense. At .001 per share, that would make the post split price to be $75.00 per share. I think that is well about the price requirement for needing to meet to be able to trade on the NASDAQ, which is why they would be doing a reverse split in the first place. I suspect what the IR was hinting at when I spoke to him that the ratio is going to be way lower. The reverse split ratio is going to be way lower in my o[pinion and I suspect it is only going to be done when the company is ready to go to the NASDAQ.
They have been growing exponentially quarter over quarter to culminate in generating $1.98 million for their 3rd Qtr. They are on track to be generating over $10 million in Revenues over their next four quarters or definitely for 2024. I think we are still very good.
v/r
Sterling
Cardiff Lexington Announces Reduction of Convertible Debt Balance
FT. LAUDERDALE, FL / ACCESSWIRE / November 17, 2023 / Cardiff Lexington Corporation (OTC PINK:CDIX) today announced that the Company has reduced its convertible debt balance with the payment of two convertible promissory notes originally issued to a single lender on February 9, 2021 and April 26, 2021, respectively. The total payment value of $175,000 is for complete and full settlement of both notes.
Alex Cunningham, Chief Executive Officer of Cardiff Lexington, commented, "We're pleased to be able to reduce our convertible debt balance with these payments. A key initiative of ours is to continue to simplify our capital structure to support our long-term growth. Payment of these notes is one example of our execution of this strategy, and our goal is to continue to significantly simplify our capital structure."
-----
About Cardiff Lexington Corporation:
Cardiff Lexington Corporation is a holding company focused on locating, acquiring, and building middle market, niche companies, primarily in the healthcare industry. Fundamental to the Cardiff Lexington strategy is the service-based partnership culture which emphasizes core values, teamwork, accountability, and performance.
A substantial majority of the Company's revenue is derived from Nova Ortho and Spine, PLLC, or Nova, which the Company acquired in May of 2021 and operates a group of regional primary specialty and ancillary care facilities throughout Florida that provide traumatic injury victims with a full range of diagnostic and surgical services, primary care evaluations, interventional pain management, and specialty consultation services.
For more information on Cardiff Lexington Corporation, you may access the company's website at https://cardifflexington.com/
Forward Looking Statements
This press release may contain information about our views of future expectations, plans and prospects that constitute forward-looking statements. All forward-looking statements are based on management's beliefs, assumptions and expectations of the Company's future economic performance, taking into account the information currently available to it. These statements are not statements of historical fact. Although the Company believes the expectations reflected in such forward-looking statements are based on reasonable assumptions, it can give no assurance that its expectations will be attained. The Company does not undertake any duty to update any statements contained herein (including any forward-looking statements), except as required by law. Forward-looking statements are subject to a number of factors, risks and uncertainties, some of which are not currently known to us, that may cause the Company's actual results, performance or financial condition to be materially different from the expectations of future results, performance or financial position. Actual results may differ materially from the expectations discussed in forward-looking statements. Factors that could cause actual results to differ materially from expectations include general industry considerations, regulatory changes, changes in local or national economic conditions and other risks set forth in "Risk Factors" included in our filings with the Securities and Exchange Commission.
Contact:
Cardiff Lexington Investor Relations
investorsrelations@cardifflexington.com
(800) 628-2100 ext. 705
or
IMS Investor Relations
cardifflexington@imsinvestorrelations.com
(203) 972-9200
SOURCE: Cardiff Lexington Corporation
View source version on accesswire.com:
https://www.accesswire.com/804723/cardiff-lexington-announces-reduction-of-convertible-debt-balance
© Copyright 2023 ACCESSWIRE. All Rights Reserved.
https://www.otcmarkets.com/stock/CDIX/news/story?e&id=2694955
Cardiff Lexington Announces Third Quarter 2023 Financial Results
Revenue Growth and Significant Margin Improvement Drives Increase in Quarterly Net Income to $1.98 Million -
FT. LAUDERDALE, FL / ACCESSWIRE / November 15, 2023 / Cardiff Lexington Corporation (OTC PINK:CDIX) announced today financial results for its third quarter ended September 30, 2023.
Third Quarter Financial Highlights
9.8% growth in the Company's healthcare division drove 3.5% consolidated revenue growth to $3.4 million
83% gross profit margin in the Company's healthcare division up from 64.7% last year drove consolidated gross profit margin to 79.6% for the quarter
Operating income increased 52% to $2.3 million, or 67% of sales from $1.5 million, or 45% of sales in Q3 last year due to a deliberate focus on higher margin business and disciplined cost containment
Net income increased 415% to $1.98 million from a loss of $628,000 in Q3 last year
Nine Month Financial Highlights
16.2% growth in the Company's healthcare division drove 5.1% consolidated revenue growth to $9.8 million
72.7% gross profit margin in the Company's healthcare division up from 63.4% last year drove consolidated gross profit margin to 73% for the nine-month period
Operating income increased 41% to $4.7 million, or 47.9% of sales from $3.3 million, or 35.7% of sales in the nine-month period last year due to a deliberate focus on higher margin business and disciplined cost containment
Net income increased 247% to $2.8 million from a loss of $1.9 million in the comparable nine-month period last year
Balance Sheet Highlights at September 30, 2023
39% increase in total assets to $18.5 million compared to December 31, 2022
250% increase in stockholders' equity to $975,351 from a negative shareholders' equity of $1.47 million at December 31, 2022
Slightly positive working capital compared to a negative working capital at December 31, 2022
https://www.accesswire.com/users/newswire/images/803432/cardiff-img1.png
Alex Cunningham, Cardiff Lexington CEO, stated, "Results from our most recent third quarter reflect the culmination of efforts over the past several years to successfully position the Company within a growing healthcare sector, implement efficiencies, and streamline operations. We have taken the actions necessary to achieve and report sustainable, profitable results over consecutive quarters. Net income has reached $2.8 million thus far in 2023 which represents significant, quantifiable advancement for the Company. We expect this number to continue to grow moving forward as we begin to see the impact of the additional working capital being deployed from our new revolving financing.
Mr. Cunningham continued, "In conjunction with our significantly improving results from operations, we continue to prepare for a targeted early 2024 uplisting to a major exchange. To that end have filed with FINRA for the required share consolidation and also anticipate updating and amending our S1 registration filing to include 2023 Q3 results. In conjunction with this uplisting, it is also our intention to simplify our capital structure to best support our long term growth for shareholders."
-----
About Cardiff Lexington Corporation:
Cardiff Lexington Corporation is a holding company focused on locating, acquiring, and building middle market, niche companies, primarily in the healthcare industry. Fundamental to the Cardiff Lexington strategy is the service-based partnership culture which emphasizes core values, teamwork, accountability, and performance.
A substantial majority of the Company's revenue is derived from Nova Ortho and Spine, PLLC, or Nova, which the Company acquired in May of 2021 and operates a group of regional primary specialty and ancillary care facilities throughout Florida that provide traumatic injury victims with a full range of diagnostic and surgical services, primary care evaluations, interventional pain management, and specialty consultation services.
For more information on Cardiff Lexington Corporation, you may access the company's website at https://cardifflexington.com/
FORWARD LOOKING STATEMENT: This news release contains forward looking statements within the meaning of the Securities Litigation Reform Act. The statements reflect the Company's current views with respect to future events that involve risks and uncertainties. These risks include the failure to meet schedule or performance requirements of the Company's business, the Company's liquidity position, the Company's ability to obtain new business, the emergence of competitors with greater financial resources, and the impact of competitive pricing. In the light of these uncertainties the forward-looking events referred to in this release might not occur.
Cardiff Lexington Investor Relations
investorsrelations@cardifflexington.com
(800) 628-2100 ext. 705
or
IMS Investor Relations
cardifflexington@imsinvestorrelations.com
(203) 972-9200
CARDIFF LEXINGTON CORPORATION AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
FOR THE THREE AND NINE MONTHS ENDED SEPTEMBER 30, 2023 AND 2022
(UNAUDITED)
https://www.otcmarkets.com/stock/CDIX/news/story?e&id=2692317
Bullish
$CDIX - work your magic GC! I know you have it in you!
so easy to get this stock going. very thin. I am wondering if the CFO that bought 109M shares yesterday is aware about the RS too! LOL
$CDIX - profit takers above $0.001 are buying their shares back at $0.0007 and $0.0008 ... IMO
$CDIX - if IR said that they won't execute an RS of 1:75,000 then why would they lie! I believe that they will use it as a catalyst to push PPS higher!
Just my opinion though!
|
Followers
|
293
|
Posters
|
|
|
Posts (Today)
|
0
|
Posts (Total)
|
36816
|
|
Created
|
06/10/11
|
Type
|
Free
|
| Moderators | |||
AI
